PepGen | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.52, beating the estimate of USD -0.565.

EBIT: As of FY2025 Q3, the actual value is USD -19.29 M.

Cash, Cash Equivalents and Marketable Securities

• As of September 30, 2025, PepGen Inc. reported cash, cash equivalents, and marketable securities totaling $163.7 million.

Research and Development Expenses

• Research and Development Expenses were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024.

General and Administrative Expenses

• General and Administrative Expenses were $5.2 million for the three months ended September 30, 2025, compared to $5.4 million for the same period in 2024.

Net Loss

• Net Loss was $18.0 million, or - $0.52 basic and diluted net loss per share, for the three months ended September 30, 2025, compared to $21.4 million, or - $0.66 basic and diluted net loss per share, for the same period in 2024.

Operating Loss

• Operating loss was - $18.7 million for the three months ended September 30, 2025, compared to - $23.2 million for the same period in 2024.

Total Assets

• Total assets were $190.1 million as of September 30, 2025, compared to $150.9 million as of December 31, 2024.

Liabilities and Stockholders’ Equity

• Liabilities were $26.9 million as of September 30, 2025, compared to $32.3 million as of December 31, 2024.
• Stockholders’ equity was $163.1 million as of September 30, 2025, compared to $118.6 million as of December 31, 2024.

Outlook / Guidance

• PepGen Inc. expects to report results from the 5 mg/kg cohort of the FREEDOM2 trial in the first quarter of 2026 and plans to initiate dosing in the 10 mg/kg cohort during the same quarter.
• The recent $115 million financing extends the company’s cash runway into the second half of 2027.
• The company remains on track to report results from the 10 mg/kg cohort in the second half of 2026.